Russell Anderson

Russell Anderson counsels companies through a broad range of domestic and cross-border M&A and venture capital transactions with a focus on the tech and life sciences sectors. Russell was previously seconded to a major financial institution where he advised on a number of asset sales and corporate governance issues as part of the EMEA consumer legal team. He is a co-chair of the firm’s LGBTQ+ Affinity Group and a member of the firm's pro bono committee.

His recent experience includes advising:

• AAC Clyde Space on its acquisition of SpaceQuest, a satellite technology developer based in Virginia
• Adestra, a provider of email, marketing and transaction automation software, on its sale to Upland for $56 million
• Alvotech Holdings, a global biopharmaceutical company, on its combination with special purpose acquisition company (SPAC) Oaktree Acquisition Corp. II, with the combined company valued at $2.25 billion
• Bit Bio, a synthetic biology company, on its $41 million Series A financing
• Brandwatch, a global leader in digital consumer intelligence and social media listening, on its agreement to sell to Cision for $450 million
• Brandwatch, the world’s premier social suite, on its acquisition of Paladin, a comprehensive influencer marketing platform
• Chegg in connection with its acquisition of Busuu for approximately $436 million
• Cision, a global comprehensive communications platform, on its acquisition of Factmata, an advanced social and news media monitoring company
• Cisco on its bolt on acquisition of Ensoft, a specialist in developing network software
• DocuSign, on its $188 million acquisition of Seal Software
• HitGen, on its acquisition of research company, Vernalis Research (R&D) Limited, from Ligand Pharmaceuticals
• Hummingbird Bioscience, a clinical-stage biotech company, on its US$19 million Series B financing
• Luna Innovations, a developer of fibre-optics based technologies, on its acquisition of OptaSense from QinetiQ
• Mission Therapeutics, a drug discovery and development company, on its £12 million Series B financing
• Redx Pharma, a UK clinical-stage biotechnology company, on its all share merger with Jounce Therapeutics, a US clinical-stage immunotherapy company, in a $425 million and contingent value right transaction.
• Style Analytics Limited, a factor and ESG exposure analytics provider, on its sale to Investment Metrics
• Tusk Therapeutics, a UK immuno-oncology company, on its sale to Roche for up to $759 million
• UiPath in connection with its acquisition of Re:Infer

Pro bono

Russell regularly advises not-for profits and charities on corporate governance issues.